Specialty Generics - Global Market Trajectory & Analytics

Description Table of
Contents

Global Specialty Generics Market to Reach $207.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Specialty Generics estimated at US$63.5 Billion in the year 2020, is projected to reach a revised size of US$207.4 Billion by 2027, growing at a CAGR of 18.4% over the period 2020-2027. Injectables, one of the segments analyzed in the report, is projected to record 19.6% CAGR and reach US$149.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Types segment is readjusted to a revised 15.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 18% CAGR

The Specialty Generics market in the U.S. is estimated at US$18.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$36.4 Billion by the year 2027 trailing a CAGR of 18% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.5% and 15.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR.

Select Competitors (Total 43 Featured):

Akorn Inc.
Apotex Corp.
Endo International plc.
Mallinckrodt
Mylan N.V.
Pfizer Inc.
Sandoz International GmbH
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Industries
Valeant Pharmaceuticals

Note: Product cover images may vary from those shown

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Current & Future Analysis for Specialty Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Specialty Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Specialty Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 8: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Inflammatory Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Hepatitis C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
Table 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 26: USA Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 27: USA 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 28: USA Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 29: USA Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 30: USA 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
CANADA
Table 31: Canada Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 32: Canada Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 33: Canada 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 34: Canada Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 35: Canada Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 36: Canada 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
JAPAN
Table 37: Japan Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 38: Japan Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 39: Japan 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 40: Japan Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 41: Japan Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 42: Japan 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
CHINA
Table 43: China Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 44: China Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 45: China 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 46: China Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 47: China Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 48: China 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
EUROPE
Table 49: Europe Current & Future Analysis for Specialty Generics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 50: Europe Historic Review for Specialty Generics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 51: Europe 15-Year Perspective for Specialty Generics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Table 52: Europe Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 53: Europe Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 54: Europe 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 55: Europe Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 56: Europe Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 57: Europe 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
FRANCE
Table 58: France Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 59: France Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 60: France 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 61: France Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 62: France Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 63: France 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
GERMANY
Table 64: Germany Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 65: Germany Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 66: Germany 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 67: Germany Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 68: Germany Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 69: Germany 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
ITALY
Table 70: Italy Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 71: Italy Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 72: Italy 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 73: Italy Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 74: Italy Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 75: Italy 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 76: UK Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 77: UK Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 78: UK 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 79: UK Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 80: UK Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 81: UK 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 82: Rest of Europe Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 83: Rest of Europe Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 84: Rest of Europe 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 85: Rest of Europe Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 86: Rest of Europe Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 87: Rest of Europe 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 88: Asia-Pacific Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 89: Asia-Pacific Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 90: Asia-Pacific 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 91: Asia-Pacific Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 92: Asia-Pacific Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 93: Asia-Pacific 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027
REST OF WORLD
Table 94: Rest of World Current & Future Analysis for Specialty Generics by Type - Injectables and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 95: Rest of World Historic Review for Specialty Generics by Type - Injectables and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 96: Rest of World 15-Year Perspective for Specialty Generics by Type - Percentage Breakdown of Value Sales for Injectables and Other Types for the Years 2012, 2020 & 2027
Table 97: Rest of World Current & Future Analysis for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 98: Rest of World Historic Review for Specialty Generics by Application - Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Table 99: Rest of World 15-Year Perspective for Specialty Generics by Application - Percentage Breakdown of Value Sales for Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 43

Note: Product cover images may vary from those shown

RELATED TAGS

RELATED PRODUCTS

Inhalation and Nasal Spray Generic Drugs - Global Market Trajectory & Analytics

Generic Oncology Drugs Market to 2027 - Global Analysis and Forecasts by Molecular Type; Indication, and Geography

Generic Drugs - Global Market Trajectory & Analytics

Generic Oncology Drugs Market by Molecule, by Administration Route, and by Distribution Channel: Global Market Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025

Generics Global Industry Guide 2015-2024